Semax: a nootropic peptide under FDA reclassification
A peptide with a specific structural lineage, real clinical use in Russia, and a regulatory status in the US that is actively evolving.
TL;DR
- Semax is a heptapeptide derived from the ACTH(4-10) fragment — the part of adrenocorticotropic hormone associated with cognitive effects rather than cortisol production.
- Russian clinical practice has used semax for stroke rehabilitation and cognitive indications since the 1990s; FDA has not evaluated it.
- FDA removed semax from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.
What it is
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of ACTH(4-10), a seven-amino-acid sequence within the larger adrenocorticotropic hormone (ACTH) molecule. The ACTH(4-10) fragment was identified in the 1970s as carrying the peptide's cognitive and behavioral effects — distinct from the steroidogenic (cortisol-releasing) activity of the full ACTH molecule. Researchers at the Institute of Molecular Genetics in Moscow modified the sequence with a C-terminal Pro-Gly-Pro extension to improve metabolic stability. The resulting peptide, semax, is administered intranasally. In Russia, it has been used clinically for stroke, cognitive decline, and optic nerve conditions for several decades.
How it works
Semax's primary proposed mechanism centers on increasing levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in specific brain regions. BDNF supports the survival and differentiation of existing neurons and the growth of new ones — a process called neuroplasticity. Animal research has also shown semax influences dopaminergic and serotonergic activity. The intranasal route bypasses the blood-brain barrier more effectively than other delivery methods for some peptides. As with selank, the clinical translation of these animal and in vitro findings to humans has not been fully established through independent controlled trials.
Who asks about it
Semax surfaces in conversations about cognitive performance, focus, and neuroprotection — particularly in the context of age-related changes in mental sharpness. It also comes up in discussions of peptides for mental health support, given its neurotrophic mechanisms. The cognitive longevity angle resonates with the same audience interested in proactive brain health strategies.
What the research says
A clinical study published in Cerebrovascular Diseases (Skvortsova et al., 2006) evaluated semax in ischemic stroke patients and reported improvements in neurological outcomes compared to placebo over a 10-day treatment period. The study population was specific — acute stroke — and the findings may not generalize to healthy individuals using it for cognitive support. In vitro and rodent studies have documented BDNF upregulation and neuroprotective effects in models of oxidative stress and ischemia. A review by Dolotov et al. (2006) in the Journal of Molecular Neuroscience examined semax's neurotrophic mechanisms in more detail. No US-based Phase I/II clinical trials appear on ClinicalTrials.gov as of this writing.
What to know before considering it
Semax is not FDA-approved. FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. Intranasal administration also carries pharmacokinetic variables — absorption rates differ by individual anatomy, mucosal health, and other factors — that make dose standardization more complicated than injectable routes.
The Halftime POV
Semax is one of the more scientifically grounded compounds in the nootropic-peptide space, with a clearer mechanistic story (BDNF/NGF upregulation) and a longer clinical history than most. The honest limitation is that the history lives in a different regulatory universe than the FDA. That matters — not because Russian research is inherently lower quality, but because independent replication in diverse populations with rigorous blinding is how the clinical field builds confidence. Semax is worth watching as the reclassification process unfolds.
Related reading:
FAQ
Q: What is Semax? A: Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence of adrenocorticotropic hormone. It was developed in Russia and has been used clinically there for ischemic stroke, cognitive impairment, and optic nerve disease. It is administered intranasally or by injection. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.
Q: What does the published research show about Semax? A: Russian clinical studies describe neuroprotective effects in ischemic stroke models and cognitive improvements in patients with neurocognitive disorders. The compound has been in clinical use in Russia for several decades. US peer-reviewed trial data is absent — the evidence base is real but not FDA-reviewed and not replicated in Western randomized controlled trials.
Q: Is Semax available through a US compounding pharmacy? A: FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Disclaimer
Semax was previously in FDA's Category 2. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Skvortsova VI et al. "Clinical and neurophysiological effects of semax in the acute period of hemispheric stroke." — Zh Nevrol Psikhiatr, 2003
- Dolotov OV et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." — J Mol Neurosci, 2006
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is Semax?
Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence of adrenocorticotropic hormone. It was developed in Russia and has been used clinically there for ischemic stroke, cognitive impairment, and optic nerve disease. It is administered intranasally or by injection. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.
What does the published research show about Semax?
Russian clinical studies describe neuroprotective effects in ischemic stroke models and cognitive improvements in patients with neurocognitive disorders. The compound has been in clinical use in Russia for several decades. US peer-reviewed trial data is absent — the evidence base is real but not FDA-reviewed and not replicated in Western randomized controlled trials.
Is Semax available through a US compounding pharmacy?
FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.